PHARMACOLOGICAL AND BIOCHEMICAL MECHANISMS OF ACTION OF METFORMIN IN TYPE 2 DIABETES MELLITUS (LITERATURE REVIEW)

Authors

  • Xayrullayeva A.X. Tashkent state medical university, Tashkent, Republic of Uzbekistan, Scientific supervisor: Mirzaahmedova K.T (TashSMU)
  • Bahodirova D.B. Tashkent state medical university, Tashkent, Republic of Uzbekistan, Scientific supervisor: Mirzaahmedova K.T (TashSMU)
  • Abdubannoyeva M.A. Tashkent state medical university, Tashkent, Republic of Uzbekistan, Scientific supervisor: Mirzaahmedova K.T (TashSMU)

Keywords:

metformin, type 2 diabetes mellitus, AMPK, gluconeogenesis, insulin sensitivity, mitochondrial complex I, GLUT4, lactic acidosis, gut microbiota.

Abstract

According to the World Health Organization, the number of patients with diabetes mellitus worldwide continues to increase steadily year by year, with more than 90% of cases being attributable to type 2 diabetes mellitus. The disease reduces patients’ quality of life through cardiovascular, renal, ocular, and nervous system complications and places a substantial economic burden on healthcare systems. Therefore, the treatment of the disease with pathogenetically justified, safe, and effective therapeutic agents remains one of the key challenges in modern medical practice. Metformin has been used as a first-line pharmacological agent for the treatment of type 2 diabetes mellitus for several decades. However, its molecular and biochemical mechanisms of action continue to be actively investigated and supplemented by new findings, including its effects on the gut microbiota and glucagon-like peptide-1 (GLP-1) secretion. Therefore, a comprehensive and systematic analysis of the pharmacodynamic and biochemical basis of metformin’s effects is relevant not only from a practical clinical perspective but also as a scientific and theoretical foundation for the development of novel glucose-lowering agents, thereby emphasizing the relevance of this topic.

References

Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin // Diabetologia. -2017.

Foretz M., Guigas B., Bertrand L., Pollak M., Viollet B. Metformin: from mechanisms of action to therapies // Cell Metabolism. - 2014.

Pernicova I., Korbonits M. Metformin - mode of action and clinical implications for diabetes and cancer // Nature Reviews Endocrinology. - 2014.

Katsyuba E., Romani M., Hofer D., Auwerx J. NAD+ homeostasis in health and disease // Nature Metabolism. - 2020.

Wu H., Esteve E., Tremaroli V. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes // Nature Medicine. -2017.

Каримов Ш.И., Ниязов А.А. Клиник фармакология асослари. - Тошкент: Тиббиёт, 2019.

Мансурова М.Х., Раимова З.Б. Ички касалликлар: эндокрин тизим патологиялари. - Тошкент: Ўзбекистон, 2021.

American Diabetes Association. Standards of Medical Care in Diabetes // Diabetes Care. - 2023.

Downloads

Published

2026-09-21